Layperson summaries of clinical trial results: Useful resources in the vacuum of regulatory guidance

Claire L. Gillow

Volume 24, Issue 4 - Writing for Lay Audiences

Layperson summaries of clinical trial results: Useful resources in the vacuum of regulatory guidance

Author: Claire L. Gillow

Abstract

To meet the requirements of the clinical trial regulation, preparation for the publication of lay summaries on the European database should be undertaken as soon as possible. However, as of July 2015 (at the time of writing this article), no regulatory guidance has been produced. The main goal of this article is to raise awareness of other resources that writers can use in the interim. This includes templates, guidance, and examples published by the Harvard Workgroup and the Center for Information and Study on Clinical Research Participation, whose work is supported by the EMA and FDA.

Keywords: Disclosure, Layperson Summary, The Harvard Workgroup, The Center for Information and Study on Clinical Research Participation

Download the full article

References

Sood A, Prasad K, Chhatwani L, Shinozaki E, Cha SS, Loehrer LL, et al. Patients’ attitudes and preferences about participation and recruitment strategies in clinical trials. Mayo Clin Proc. 2009;84(3):243–7. Available from: http://www.mayoclinicproceedings.org/article/S0025-6196(11)61141-5/references
Getz K. Public confidence and trust today. A review of public opinion polls. Monitor. 2008:17–21. Available from: http://www.acrpnet.org//PDF/Monitor/MonitorArchive/Sept2008/11312-05_Getz1.pdf
European Parliament. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. OJEU. 2014;L158:1–76. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2014_536/reg_2014_536_en.pdf
Sroka-Saidi K, Boggetti B, Schindler TM. Transferring regulation into practice: The challenges of the new layperson summary of clinical trial results. EMWA. 2015;24(1):24–27. Available from: http://www.maneyonline.com/doi/abs/10.1179/2047480614Z.000000000274?journalCode=mew
European Parliament. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. OJEU. 2001;L121:34–44. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF
ICH. E3 Implementation Working Group. ICH E3 Guideline: Structure and content of clinical study reports questions & answers. 2012 Jun. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Q_As_Step4.pdf
EPF. EPF position: Clinical trial results – communication of the lay summary. 2015 Mar. Available from: http://www.eu-patient.eu/globalassets/policy/clinicaltrials/epf-lay-summary-position-march-2015.pdf
US Government. FDAAA. Title VIII - Clinical trial databases. Public Law 110-85. 2007 Sep;121 stat:904-922. Available from: http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf
MRCT. Return of results guidance document. Version 1.0. 2015 Mar. Available from: http://mrctcenter.org/files/mrct/files/2015-03-19_mrct_ror_guidance_1.0.pdf
The MRCT Center at Harvard. Return of results toolkit. Version 1.0. 2015 Mar. Available from: http://mrctcenter.org/files/mrct/files/2015-03-19_mrct_ror_toolkit_1.0.pdf
Ciscrp.org. CISCRP trial results summaries c2015 [cited 2015 Aug 29]. Available from: https://www.ciscrp.org/programs-events/trial-results/results-summaries/
Ctep.cancer.gov. CTCAE v4.0 terms with lay terms [cited 2015 Aug 29]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae_4_with_lay_terms.pdf
Medicines.org.uk. EMC [Cited 2015 Aug 29]. Available from: http://www.medicines.org.uk/emc/
European Commission. Guideline on the readability of the labelling and package leaflet of medicinal products for human use. Revision 1. 2009 Jan. Available from: http://ec.europa.eu/health/files/eudralex/vol-2/c/2009_01_12_readability_guideline_final_en.pdf
Ema.europa.eu. c1995-2015 EMA [cited 2015 Aug 29]. Examples of EPAR and RMP for Plegridy™. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002827/human_med_001782.jsp&mid=WC0b01ac058001d124
Raynor DK, Bryant D. European public assessment report (EPAR) summaries for the public: are they fit for purpose? A user-testing study. BMJ Open. 2013;3(9). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780304/
Cancerresearchuk.org. Cited 2015 Aug 29. Note: click on about cancer, clinical trials, type in drug name, tick ‘have results available’ search, select clinical trial and click on trial results + to show lay results. Available from: http://www.cancerresearchuk.org/
Bouder F, Way D, Loefstedt R, Evensen D. Transparency in Europe: a quantitative study. Risk Anal. 2015;35(7):1210–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25931009

Volume 24, Issue 4 - Writing for Lay Audiences

Layperson summaries of clinical trial results: Useful resources in the vacuum of regulatory guidance

Author: Claire L. Gillow

Abstract

References

Search

Articles

Links

Editoral Board